Sun Pharmaceutical Industries Limited

Sun Pharma Advanced Research Company Limited

Sun Pharmacuetical Industries Ltd.

Sun Pharmaceutical Indsutries Ltd.

Prashant Kane

Subhas Balaram Bhowmick

Samarth Kumar

Maheshkumar Parasmal Soni

Kirti Ganorkar

Nishit Patel

Ramaji Karshanbhai Varu

Nisarg Bipinchandra Mistry

Sudeep Kumar Agrawal

Satish Madhukar Gokhale

Satyashodhan Babasaheb Patil

Raman Lad

Kartik Nagar

Sapna Fadnis

Mark Hagler

Shantaram Pawar

Milan Mohanbhai Vasoya

Praveen Kumar Srivastava

Abhijit Takale

Amar Rana

Kandarp Maheshkumar Dave

Milan Natvarbhai Thakkar

Alex George

Swapnil Ramesh Patil

Rajamannar Thennati

Nitin Bhalachandra Dharmadhikari

Simon James Smith

Yashoraj Rupsinh Zala

David Stuart Harris

Richard Francis Day

Lee Wood

Jonathan Wilkins

Rakesh Thummar

Duncan Aleck Bishop

Alok B Namdeo

Satyashodhan Patil

Umeshkumar Mukeshbhai Patel

Ashish Anilrao Dubewar

Matthew David Allen

Becky Lynn Pilditch

Samantha Anne Musgrave

Ganesh Sangaiah

Soni Maheshkumar Parasmal

Madhusudhan Bommagani

Vaibhav Dubey

Manish Ramdas Bagul

Nachiket Vilas Gole

Balaram Subhas Bhowmick

Anilrao Ashish Dubewar

Mukeshbhai Umeshkumar Patel

Jonathan Hugh Wilkins

Ajay Nandgaonkar

Ramaji Karshanbhai Mistry

Hishit Patel

Subhas Balaram Browmick

Subhas B Bhowmick

A parenteral dosage form having an infusion container filled with an aqueous solution in volumes ranging from 40 ml to 500 ml comprising 1 mg/ml to 2 mg/ml of carboplatin, wherein the solution contains known impurity of 1, 1-cyclobutanedicarboxylic acid in an amount of not more than 1.0% by weight of carboplatin and the solution remains physically stable when stored at room temperature.

Parenteral dosage form of carboplatin

The present invention refers to an intravenous infusion dosage form comprising a composition containing pemetrexed or its pharmaceutically acceptable salt, an osmagent and an aquous vehicle. The composition is present in a flexible infusion container containing an inert gas in the headspace. Additionally, a second container may be present surrounding the flexible infusion container.

Intravenous infusion dosage form

A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 μg/mL. The method further includes permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter. The injector is configured to provide at least one audible feedback during the rotation. The method further includes operating the actuator to deliver the octreotide acetate from the cartridge through the needle to treat the subject. The injector is provided with multiple surface portions.

Method of injecting octreotide acetate into the body

The present invention relates to a dosage form comprising an aqueous solution of a vinca alkaloid drug or its pharmaceutically acceptable salt in a flexible infusion container, and a light protective secondary packaging containing the flexible infusion container, wherein the dosage form is ready-to-infuse and wherein the aqueous solution is stable at room temperature.

Dosage form of vinca alkaloid drug

The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, wherein the said solution is stable for a prolonged period of time and can be terminally sterilized by autoclaving.

Infusion dosage form of norepinephrine

A perfusion container for directly administering to patients a dose of an antineoplastic drug calculated according to a patient's parameter, wherein the first perfusion container comprises a solution of antineoplastic drug at a concentration and volume such that the amount of antineoplastic drug in the container is equal to the calculated dose for one patient but less than the calculated dose for a second patient, the calculated dose is provided to first patient within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container, further the first perfusion container is accompanied by a second top-up perfusion container comprising a solution of antineoplastic drug at a concentration and volume such that the calculated dose is provided within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container and the second top-up container to the second patient.

Perfusion system

The invention relates to an infusion container comprising a sterile, ready-to-use, stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof, suitable for direct intravenous infusion to a patient in need thereof. The invention also relates to a novel infusion container having plurality of ports that is suitable for delivering or receiving a sterile fluid, such as the said stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof.

Infusion bag of Midazolam for intravenous use

The present invention relates to a method for enabling hospitals or clinics to administer a dose of a drug to patients in need thereof while avoiding steps of manipulation, dilution, reconstitution, dispensing, sterilization, transfer, handling or compounding before intravenous administration. The present invention further relates to a perfusion system comprising different sets of perfusion containers, each container comprising a ready-to-infuse, stable, sterile, aqueous perfusion solution of a drug, wherein the set of perfusion containers alone or in combination provides for direct intravenous administration of a desired dose of the drug to a patient in need thereof, such that the delivered dose is equal to or within &#xb1;5% of the calculated dose.

Perfusion dosage form

A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 &#x3bc;g/mL. The method further includes providing, on the injector, a plurality of indicia only at prescribed doses of 50 &#x3bc;g, 100 &#x3bc;g, 150 &#x3bc;g and 200 &#x3bc;g settable via the dose setter without indicia between said prescribed doses; and permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter, wherein the injector is configured to provide at least one audible feedback during the rotation.

Infusion bag of midazolam for intravenous use

Growing community of inventors

Baroda, India

Prashant Kane